{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T12:21:29Z","timestamp":1790166089730,"version":"4.1.0"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,1]]},"DOI":"10.1097\/inf.0b013e3181fe05af","type":"journal-article","created":{"date-parts":[[2010,11,1]],"date-time":"2010-11-01T03:24:36Z","timestamp":1288581876000},"page":"e9-e17","source":"Crossref","is-referenced-by-count":86,"title":["Live-attenuated Tetravalent Dengue Vaccine in Dengue-na\u00efve Children, Adolescents, and Adults in Mexico City"],"prefix":"10.1097","volume":"30","author":[{"given":"Jorge","family":"Poo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Galan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Remi","family":"Forrat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Betzana","family":"Zambrano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Lang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustavo H.","family":"Dayan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-33-20210202","first-page":"223","article-title":"Epidemiology of Arthropod-Borne Viral Disease.","author":"Gubler","year":"1988"},{"key":"R2-33-20210202","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/S0022-3476(97)70054-4","article-title":"Dengue virus infection: epidemiology, pathogenesis, clinical presentation, diagnosis, and prevention.","volume":"131","author":"Kautner","year":"1997","journal-title":"J Pediatr"},{"key":"R3-33-20210202","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0140-6736(97)12483-7","article-title":"Dengue and dengue haemorrhagic fever.","volume":"352","author":"Rigau-Perez","year":"1998","journal-title":"Lancet"},{"key":"R4-33-20210202","doi-asserted-by":"crossref","first-page":"684","DOI":"10.4269\/ajtmh.2006.74.684","article-title":"Volume replacement in infants with dengue hemorrhagic fever\/dengue shock syndrome.","volume":"74","author":"Nguyen","year":"2006","journal-title":"Am J Trop Med Hyg"},{"key":"R5-33-20210202","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0891-5520(05)70221-X","article-title":"Dengue and dengue hemorrhagic fever in Latin America and the Caribbean.","volume":"14","author":"Ist\u00fariz","year":"2000","journal-title":"Infect Dis Clin North Am"},{"key":"R6-33-20210202","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S1386-6532(03)00010-6","article-title":"Dengue and dengue hemorrhagic fever in the Americas: lessons and challenges.","volume":"27","author":"Guzman","year":"2003","journal-title":"J Clin Virol"},{"key":"R7-33-20210202","doi-asserted-by":"crossref","first-page":"128","DOI":"10.4269\/ajtmh.2010.09-0346","article-title":"The epidemiology of dengue in the Americas over the last three decades: a worrisome reality.","volume":"82","author":"San martin","year":"2010","journal-title":"Am J Trop Med Hyg"},{"key":"R9-33-20210202","doi-asserted-by":"crossref","first-page":"7290","DOI":"10.1128\/JVI.75.16.7290-7304.2001","article-title":"Construction, safety, and immunogenicity in nonhuman primates of a chimeric yellow fever-dengue virus tetravalent vaccine.","volume":"75","author":"Guirakhoo","year":"2001","journal-title":"J Virol"},{"key":"R10-33-20210202","doi-asserted-by":"crossref","first-page":"5477","DOI":"10.1128\/JVI.74.12.5477-5485.2000","article-title":"Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and protective in nonhuman primates.","volume":"74","author":"Guirakhoo","year":"2000","journal-title":"J Virol"},{"key":"R11-33-20210202","doi-asserted-by":"crossref","first-page":"60","DOI":"10.4161\/hv.2.2.2555","article-title":"Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes.","volume":"2","author":"Guirakhoo","year":"2006","journal-title":"Hum Vaccin"},{"key":"R12-33-20210202","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1086\/649916","article-title":"A novel tetravalent dengue vaccine is well tolerated and immunogenic against all 4 serotypes in flavivirus-naive adults.","volume":"201","author":"Morrison","year":"2010","journal-title":"J Infect Dis"},{"key":"R13-33-20210202","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jviromet.2008.03.026","article-title":"Standardized quantitative RT-PCR assays for quantitation of yellow fever and chimeric yellow fever-dengue vaccines.","volume":"151","author":"Mantel","year":"2008","journal-title":"J Virol Methods"},{"key":"R14-33-20210202","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/0035-9203(59)90021-5","article-title":"A plaque technique for the titration of yellow fever virus and antisera.","volume":"53","author":"Porterfield","year":"1959","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"R15-33-20210202","doi-asserted-by":"crossref","first-page":"74","DOI":"10.4269\/ajtmh.2005.72.74","article-title":"Replication of chimeric yellow fever virus-dengue serotype 1\u20134 virus vaccine strains in dendritic and hepatic cells.","volume":"72","author":"Brandler","year":"2005","journal-title":"Am J Trop Med Hyg"},{"key":"R16-33-20210202","doi-asserted-by":"crossref","first-page":"285","DOI":"10.4049\/jimmunol.99.2.285","article-title":"A plaque reduction test for dengue virus neutralizing antibodies.","volume":"99","author":"Russell","year":"1967","journal-title":"J Immunol"},{"key":"R17-33-20210202","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1089\/vim.2008.0007","article-title":"Guidelines for plaque-reduction neutralization testing of human antibodies to dengue viruses.","volume":"21","author":"Roehrig","year":"2008","journal-title":"Viral Immunol"},{"key":"R18-33-20210202","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1097\/01.inf.0000109289.55856.27","article-title":"Safety and immunogenicity of a three dose regimen of two tetravalent live-attenuated dengue vaccines in five- to twelve-year-old Thai children.","volume":"23","author":"Sabchareon","year":"2004","journal-title":"Pediatr Infect Dis J"},{"key":"R19-33-20210202","doi-asserted-by":"crossref","first-page":"426","DOI":"10.4269\/ajtmh.2008.78.426","article-title":"Safety and immunogenicity of a tetravalent live-attenuated dengue vaccine in flavivirus naive children.","volume":"78","author":"Simasathien","year":"2008","journal-title":"Am J Trop Med Hyg"},{"key":"R20-33-20210202","doi-asserted-by":"crossref","first-page":"264","DOI":"10.4269\/ajtmh.2002.66.264","article-title":"Safety and immunogenicity of tetravalent live-attenuated dengue vaccines in Thai adult volunteers: role of serotype concentration, ratio, and multiple doses.","volume":"66","author":"Sabchareon","year":"2002","journal-title":"Am J Trop Med Hyg"},{"key":"R21-33-20210202","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1016\/j.vaccine.2005.09.029","article-title":"Immunogenicity and safety of two live-attenuated tetravalent dengue vaccine formulations in healthy Australian adults.","volume":"24","author":"Kitchener","year":"2006","journal-title":"Vaccine"},{"key":"R22-33-20210202","doi-asserted-by":"crossref","first-page":"352","DOI":"10.4049\/jimmunol.77.5.352","article-title":"Clinical and serologic response of man to immunization with attenuated dengue and yellow fever viruses.","volume":"77","author":"Dorrance","year":"1956","journal-title":"J Immunol"},{"key":"R23-33-20210202","first-page":"4201","article-title":"Dengue 2 vaccine: dose response in volunteers in relation to yellow fever immune status.","volume":"135","author":"Scott","year":"1983","journal-title":"J Infect Dis"},{"key":"R24-33-20210202","doi-asserted-by":"crossref","first-page":"33","DOI":"10.4161\/hv.5.1.6348","article-title":"Phase 2 clinical trial of three formulations of tetravalent live-attenuated dengue vaccine in flavivirus-na\u00efve adults.","volume":"5","author":"Sun","year":"2009","journal-title":"Hum Vaccin"},{"key":"R25-33-20210202","doi-asserted-by":"crossref","first-page":"48","DOI":"10.4269\/ajtmh.2003.69.48","article-title":"Phase I trial of 16 formulations of a tetravalent live-attenuated dengue vaccine.","volume":"69","author":"Edelman","year":"2003","journal-title":"Am J Trop Med Hyg"},{"key":"R26-33-20210202","first-page":"129","article-title":"Dengue vaccine candidates in development.","volume":"338","author":"Durbin","year":"2010","journal-title":"Curr Top Microbiol Immunol"},{"key":"R27-33-20210202","doi-asserted-by":"crossref","first-page":"115","DOI":"10.4269\/ajtmh.2008.79.115","article-title":"Comparative evaluation of three assays for measurement of dengue virus neutralizing antibodies.","volume":"79","author":"Putnak","year":"2008","journal-title":"Am J Trop Med Hyg"},{"key":"R28-33-20210202","doi-asserted-by":"crossref","first-page":"5205","DOI":"10.1016\/j.vaccine.2005.07.002","article-title":"Report on a WHO consultation on immunological endpoints for evaluation of new Japanese encephalitis vaccines. Geneva: WHO; September 2\u20133, 2004.","volume":"23","author":"Hombach","year":"2005","journal-title":"Vaccine"},{"key":"R29-33-20210202","doi-asserted-by":"crossref","first-page":"4761","DOI":"10.1128\/JVI.78.9.4761-4775.2004","article-title":"Safety and efficacy of chimeric yellow fever-dengue virus tetravalent vaccine formulations in nonhuman primates.","volume":"78","author":"Guirakhoo","year":"2004","journal-title":"J Virol"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00006454-201101000-00033","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:35:40Z","timestamp":1786041340000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00006454-201101000-00033"}},"subtitle":["Randomized Controlled Phase 1 Trial of Safety and Immunogenicity"],"short-title":[],"issued":{"date-parts":[[2011,1]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0b013e3181fe05af","relation":{},"ISSN":["0891-3668"],"issn-type":[{"value":"0891-3668","type":"print"}],"subject":[],"published":{"date-parts":[[2011,1]]}}}